Document:

Exhibit 10.23

 

Agreement for the Rendering of Research Services

 

THIS
AGREEMENT for the rendering of research services (the “Agreement”)
is entered into as of June 30, 2021 (the "Effective Date") by and between Yissum Research
Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) with offices at Hi-Tech Park, Edmond
J. Safra Campus, Givat Ram, P.O.B 39135, Jerusalem 91390, Israel and Virpax Pharmaceuticals, Inc. (the “Company”)
with offices at 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312 USA.

 

Yissum and the Company hereby agree
to all of the following terms and conditions:

 

		1.	The Research Services: The
Company hereby requests that the following research services be performed via Yissum: Formulation and patent related work related to
Liposomal Bupivacaine as well as research and development work related to non-GLP animal trials (the “Research
Services”). The objectives and specifications of the Research Services shall be detailed
in the protocol attached hereto as Appendix A (the "Research Services Protocol"), which shall constitute an integral
part of this Agreement.

 

		2.	Time Schedule: The Research Services are to be performed in accordance
with the following time schedule: the Research Services shall begin on July 1, 2021 (the “Start
Date”) and shall be completed no later than November 30, 2022 (the “Completion
Date” and such period from the Start Date to the Completion Date, the “Research
Service Period”).

 

		3.	The Researcher: The Research Services will be performed by under
the supervision and responsibility of Professor Yechezkel Barenholz, or such other qualified person as may be determined and appointed
from time to time by Yissum (the “Researcher”).

 

		4.	The Scientific Report: The written scientific report that will be required as a result
of the Research Services rendered will be presented directly to the Company by the Researcher within 14 (fourteen) days of the end of
the Research Service Period (the “Scientific Report”). The
Company acknowledges that no financial report will be given by Yissum. Such Scientific Report shall include a complete summary of the
Research Services carried out including detailed protocol of the Research Services rendered.

 

		5.	The Consideration: In consideration for provision of the Research Services and the Scientific Report,
the Company shall be obligated to pay Yissum for transfer to the Researcher's laboratory budget the total sum of US$337,500 (three hundred
thirty-seven thousand five hundred US dollars), inclusive of University overhead (the "Research Services Fee"). The specific
budget items that make up the Research Services Fee are detailed in Appendix B and constitute an integral part of this Agreement. For
the avoidance of doubt, the Researcher may, where reasonably necessary or appropriate during the Research Service Period, reallocate the
Research Services Fee among the various expense categories set forth in the Research Services Budget in Appendix B. The Company shall
pay the Research Services Fee in six (6) equal quarterly payments of US $56,250 (fifty-six thousand two hundred and fifty US dollars)
as further set forth in the following paragraph.

 

The Company shall make the payment
for the first quarter (July 2021) of the Research Services Fee (US $56,250) within five (5) days of the execution of this Agreement. Each
further quarterly payment shall be made by the Company within forty-five (45) days of the presentation of a correct invoice by Yissum.
In the event that the Company fails to pay an invoiced amount in a timely manner, Yissum shall be entitled to add to the unpaid invoiced
amount an additional amount equal to annualized interest of Prime (as determined by the Bank of Israel) plus 3%, together with exchange
rate differentials, if any.

 

     

     

    

 

		6.	Intellectual Property: It is hereby agreed that the Company retains ownership in its Confidential
Information, as defined below, and in all its intellectual property rights related thereto. In addition, any intellectual property belonging
to either the Company or Yissum prior to the execution of this Agreement will remain the sole property of either the Company or Yissum,
respectively.

 

All data
generated from the provision of the Research Services, including the Scientific Report, which are specifically required and contemplated
under the Research Services Protocol, shall be owned by the Company upon full payment of the Research Services Fee (the “Company
Data”). Notwithstanding the foregoing, upon termination for any reason of the License and Sublicense Agreement by and
between Lipocure Ltd. and the Company, dated March 19, 2018 (the "LipoCureRX-Virpax Agreement"), the Company shall transfer
to Yissum all Company Data, and Yissum shall have the right, on its own or via third parties, to reference, cross-reference, review, have
access to, incorporate and use all Company Data, including in order make or to further filings and applications with any regulatory authority.
To the extent the License Agreement by and between Yissum and Lipocure Ltd, dated October 31, 2013 (the "Yissum-Lipocure License
Agreement") is in effect, the Company Data shall be deemed Licensed Technology pursuant to the Yissum-Lipocure License Agreement
and shall be deemed exclusively licensed to Lipocure pursuant to the terms of such agreement.

 

Notwithstanding the above, all rights,
title and interest in all inventions, discoveries, methods, new uses, processes or compounds, whether or not capable of registration,
and any patent applications or patents based thereon, discovered or developed by the Researcher or Dr. Shilo during the course of the
provision of the Research Services and as a result thereof shall be solely owned by Yissum (the “Yissum
Inventions”). Yissum agrees that all Yissum Inventions shall be deemed Licensed Technology
and, as such, shall be licensed to LipoCure pursuant to the Yissum Lipocure License Agreement, and LipoCureRx, as indicated by its signature
at the end of this Agreement, shall include such Yissum Inventions in the LipoCureRX-Virpax Agreement;
in both cases upon the same terms and conditions already in place in each of the Yissum-LipoCureRx Agreement and the LipoCureRx-Virpax
Agreement. Yissum hereby warrants that (a) the Researcher and the persons working under his supervision have an obligation to assign their
rights to any Yissum Inventions to Yissum; and (b) Yissum will perfect all documents necessary to effectuate the assignment of Yissum
Inventions from the Researcher and his staff to Yissum.

 

		7.	Confidentiality: Yissum and the Researcher agree to maintain the confidentiality of any information
disclosed to them by the Company in connection with the Research Services, which the Company identifies as confidential at the time of
disclosure ("Confidential Information"), and not to make public any such Confidential Information without the prior written
permission of the Company. This undertaking shall not apply to Confidential Information that is in the public domain at the time of disclosure
or thereafter enters the public domain through no fault of Yissum or the Researcher; or that the Researcher can show, by contemporaneous
written evidence, was already known to him at the time of disclosure; or that is provided to Yissum or the Researcher by a third party
having no obligations of confidentiality to the Company; or that is independently developed by an employee of the Hebrew University who
is not the Researcher. In addition, Yissum or the Researcher shall be entitled to disclose Confidential Information pursuant to a valid
judicial or administrative order, provided that they shall provide prompt notice to the Company of their receipt of such an order to allow
the Company to seek relief against such order.

 

		8.	Publications. The parties shall have the right to publish in writing in scientific journals or
orally at scientific conventions the results of their development activities, including clinical trials. Each party shall have the right
to review and comment on any material proposed for disclosure or publication by the other, its Affiliates, such as by oral presentation,
manuscript or abstract that includes Confidential Information of a party. Before any such material is submitted for publication or disclosure
(other than oral presentation materials and abstracts, which are addressed below), the publishing party shall deliver (or cause to be
delivered) a complete copy of the presentation to the other party at least 30 days prior to submitting the material to a publisher or
initiating such other disclosure, and the non- publishing party shall review any such material and give its comments to the publishing
party within 10 days of the delivery of such material to non-publishing
party which comments shall not be unreasonably rejected. Each party shall comply with the non-publishing party’s requests to delete
references to the non-publishing party’s Confidential Information or any other information that could reasonably have a negative
effect on the development of commercialization of a product in any such material and, if applicable, agrees to delay any submission for
publication or other public disclosure for a period of up to an additional 60 days for the purpose of preparing and filing appropriate
patent applications. Yissum and Researcher shall not publish or otherwise disseminate, including, but not limited to, in articles, posters,
oral presentations or other formats, any information relating to the Research without the prior written consent of Virpax. The parties
recognize that Yissum retains comparable rights of publication pursuant to the terms of the Yissum-LipoCureRx Agreement.

 

    2

     

    

 

 

		9.	Use of Names: Neither party shall make any use of any kind of the other party’s names, the
names of the other party's employees or affiliates, or the Terms of this Agreement without the prior written consent of the other party,
which consent shall not be unreasonably withheld.

 

		10.	Relationship of the Parties: The parties do not stand in a relationship of employer-employee. Such
relationship shall be that of an independent contractor.

 

		11.	Dispute Resolution: This Agreement shall be construed and governed in accordance with the laws
of England and Wales. The parties to this Agreement shall try to come to an amicable settlement of controversies or disputes arising out
of this Agreement or about its validity. Should they fail to settle them amicably, the dispute shall be settled by arbitration in accordance
with the then existing Rules of Arbitration of the International Chamber of Commerce, by which each party hereto agrees to be bound. Such
arbitration shall be held in London, England.

 

		12.	Authorized Signatories: Signature by at least two authorized representatives of Yissum on this Agreement shall constitute Yissum’s
approval and agreement to all that is written herein. The Company warrants that the person or persons signing this agreement is/are authorized
to bind the Company.

 

		13.	Disclaimer of Warranty, Liability and Indemnification:

 

		(a)	Nothing contained in this Agreement shall be construed as
a warranty on the part of Yissum that any results or inventions will be achieved by the Research Services, or that the results of the
Research Services, if any, are or will be of commercial or scientific value to the Company.

 

		(b)	Yissum and the Hebrew University,
and their respective parents, affiliates, officers, directors, employees, agents and contractors, (all such parties collectively:
the “Indemnitees”), shall not be liable for any
claims, actions, demands, losses, damages, costs and expenses (including without limitation legal fees) (collectively: “Claims”)
made, brought or suffered by the Company or by any third parties arising from any exploitation or use of
the Research Services provided (including without limitation any Research Services work product and data).

 

		(c)	In the event of any third-party Claims are brought against
any of the Indemnitees as set out above, the Company shall indemnify the relevant Indemnitees and hold them harmless from and against
any and all such damages, liability, losses, costs and/or expenses.

 

		(d)	Each party represents and warrants to the other that it has
the legal right and power to enter into this Agreement, to extend the rights granted to the other in this Agreement, and to fully perform
its obligations hereunder, and that the performance of such obligations will not conflict with its charter documents, policies or any
agreements, contracts, or other arrangements to which it is a party.

 

    3

     

    

 

		14.	Termination:

 

		(a)	Unless terminated in accordance with the provisions of this Agreement, this Agreement shall end upon the presentation of the Scientific
Report.

 

		(b)	Each party shall be entitled to terminate this Agreement in the event of a breach by the other party of
its obligations under this Agreement, including, but not limited to, any payment failure, which is not remedied by the breaching party
within 30 days of receipt of written notice from the non-breaching party.

 

		(c)	The Company may terminate this Agreement at any time upon delivery of thirty (30) days’ written
notice thereof to Lipocure. In the event of a termination pursuant to this section, unless otherwise set forth in an SOW or agreed to
by the Company, the Company shall only be responsible to pay Lipocure for Research Services performed through the date of such notice.

 

		(d)	Sections 6, 7, 8, 9, 11 and 13 shall survive termination of this Agreement.

 

		15.	Miscellaneous. This
Agreement sets forth the entire understanding between the parties with respect to the subject matter herein, and supersedes all other
agreements and discussions concerning the subject matter of this Agreement. The parties are independent contractors, and neither party
is authorized to make any warranties or representations on behalf of the other party or enter into any agreements on behalf of the other
party. If any clause of this Agreement is determined to be void or unenforceable by a court of competent jurisdiction, such clause shall
be interpreted as necessary to give maximum force to the provisions thereof, and the validity and enforceability of the remainder of
this Agreement shall not be affected. In the event of any conflict or inconsistency between the body of this Agreement and any exhibit
or SOW, the terms of the body of this Agreement shall govern, except to the extent set forth expressly otherwise in an agreed exhibit
or SOW that the terms of the exhibit or SOW shall govern. Neither party shall assign any of its rights or obligations hereunder without
the prior written consent of the other party. Assignments in violation of the foregoing shall be void. Notwithstanding the foregoing,
Virpax may assign all of its rights and obligations hereunder to an assignee of the rights of Virpax under the LipoCureRX-Virpax Agreement.
No Party shall be liable for any loss, injury or damage due to its delay or failure to perform any provision of this Agreement or any
services, when such delay or failure is caused by a force majeure event/

 

	Virpax Pharmaceuticals, Inc.
 1055 Westlakes Drive, #300

    Berwyn, PA 19312 USA	 	Yissum Research Development Company of
 the Hebrew University of Jerusalem Ltd. Hi-Tech Park,
 Edmond J.
    Safra Campus,
	 	 	Givat Ram, P.O.B 39135, Jerusalem 91390, Israel
	 	 	 
	By:	/s/ Anthony P. Mack	 	By:	/s/ Dr.
	Name: 	Anthony P. Mack	 	By:	Karen-Or Amar and /s/ Itzik Goldwaser
	Title:	Chairman and CEO	 	Name: 	 Karen-Or Amar and Itzik Goldwaser
	 	 	 	Title:	VP Business Development Healthcare and CEO

 

    4

     

    

 

Researcher’s Agreement:

 

I the undersigned, Prof. Yechezkel Barenholz of the Hebrew
University of Jerusalem, have reviewed, am familiar with and agree to all of the above terms and conditions. I hereby undertake to fully
cooperate with Yissum in order to ensure its ability to fulfill its obligations hereunder, as set forth herein.

 

	Signature:  	 	 	Date: 	 

 

Consent of LipoCureRx Ltd.:

 

LipoCureRx hereby consents to the provisions of section 6 of this Agreement
regarding the inclusion of any Yissum Inventions in the sublicense set forth in the LipoCureRx-Virpax Agreement upon the same terms and
conditions in such agreement.

 

	 	 
	Name:	 
	Title:	 
	Date:	 

 

    5

     

    

 

Appendix A

 

Work Plan of Virpax project at the Barenholz lab (June
27. 2021)

PIs: Dr Keren Turjeman (Director of Barenholz Lab
& Professor Chezy Barenholz

 

This work plan covers a period of 18 months. The Barenholz
lab will focus on three major topics

 

		1.	Optimization of the Bupisome and Bupigel formulation (Drug- product

 

		2.	Creating all what is needed to get a new (fresh IP) that will extend the lifetime of the IP for many more years after expiration of
current IP

 

		3.	Technology transfer of what was learned by the Barenholz Lab regarding 1 above (as detailed below) to Lipocure team. This process
is already in place to allow Lipocure to start working immediately

 

		4.	Animal studies although are not covered by the $250,000 budget of the grant to the Barenholz Lab will be performed on selective formulations.
It is difficult to budget it now. However minimal animal (toxicology and efficacy) will be needed. The parties agree this refers to the
studies being contemplated by Charles River Labs.

 

		1.	Optimization of the Bupisome and Bupigel formulation (Drug- product

 

		●	The optimization of the formulation will include many aspects and is aiming to study many variables that by their optimization the
current highly complex production process will be replaced by simplified and process that is expected to fit better to the obligatory
aseptic aspect of the production process. Preliminary studies indicate that such a simplification is feasible. This new step in the production
come from an un-expected results to the level it will allow to file for a new patent application. As the new IP was not yet filed, we
cannot disclose in this document more details on our new process which on one hand enables to achieve new-fresh IP without losing on the
FDA frontier what was achieved so-far

 

		●	The liposomal product variables (for both Bupisome and Bupigel) that will be studied in order obtain a new patentable process are
listed below. Firstly, the impact of each of the variables listed below will be studied, once this will be established the effect of combination
of the optimal variables will be investigated through Bupisome and Bupigel characterization. The following variables will be studied in
order to physico-chemical characterization of Bupisome and Bupigel. These variables include: size and size distribution; Zeta potential;
morphology and liposome structure (as determined by optical and electron microscopy; leakage upon storage at different temperatures; drug release in a “dissolution-
like” test. The list of variables to be studied include:

 

		o	Effect of temperature

		o	Effect on medium composition

		o	Effect of Medium pH

		o	Effect of drug concentration

		o	Comparing various methods to increase liposome trapped aqueous volume

		o	Optimization of the method to establish trans-membrane ammonium ion gradient by comparing between centrifugation to diafiltration.

 

		●	Studies toward achieving new and “young IP”

These studies are aiming to extend the protection of the
life-time of patent on the drug-product (for both Bupisome and Bupigel), at least to 2042 from 2029 of the current patent application
(allowed US patent 10,004,688 with a priority date of October 7, 2008)

It is important to note that more the 3 years of the current
patent-protection period were waisted due to the lack of funding by Virpax. The new patent application in addition to describe and protect
a new, better, and simpler way to prepare Bupisome and Bupigel will also extend the scope of the current application by the following

 

		●	To include and cover other local anesthetic of the same family of the amino amide group as bupivacaine. The common denominator of
the additional drug-substances to be studied is their ability to be remote actively loaded by same method used for bupivacaine remote
active loading (trans-membrane ammonium ion gradient). In all cases liposomes of a large trapped aqueous volume will be used. The additional
drug-substances includes lidocaine, and ropivacaine, as well as their combinations with bupivacaine. A combination of lidocaine with either
bupivacaine or ropivacaine which enables to achieve an immediate analgesia

 

		●	To include and cover few hydrogels in either cross- linked and non-crosslinked forms.

 

		●	To study both drug-loaded lipospmes having large trapped-volume alone (as-is) as well as these drug-loaded liposomes embedded in the
preferred hydrogel to get a complete characterization

 

		●	All the factors described above will be studied for liposomes and Lipogels and that are remote actively loaded with either lidocaine
or with ropivacine.

 

    6

     

    

 

Appendix B

 

A budget for the Research, including at least the
following categories:

 

	a. Personnel	100%

 

The budget is defined as quarterly payment in item
5 of the agreement

 

 

7Exhibit 10.1

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT
AGREEMENT (this “Agreement”) is made and entered into, effective as of September 8, 2021(the “Effective
Date”), by and between Georgette C. Nicholas (hereinafter referred to as the “Executive”), and Midwest Holding Inc.,
a Delaware corporation (hereinafter referred to as “MHI” or the “Employer”). Executive and MHI are
sometimes referred to in this Agreement individually as a “Party” and together as the “Parties.”

 

WHEREAS, MHI operates as a
financial services holding company, and through its subsidiaries, MHI focuses on the underwriting, selling and servicing of life and annuity
insurance products (the “Business”);

 

WHEREAS, MHI desires to employ
Executive as the President and Chief Financial Officer (“CFO”) of MHI, on the terms and conditions hereinafter set forth;
and

 

WHEREAS, Executive desires
to accept employment as set forth above on the terms and conditions hereinafter set forth.

 

W I T N E S E T H

 

NOW, THEREFORE, the Parties,
in consideration of their respective promises and undertakings as herein set forth, agree as follows:

 

1.           Employment.
The Employer will initially employ Executive as its President and CFO subject to the terms and conditions set forth herein.

 

2.          Term.
The Employer shall employ Executive and Executive shall serve the Employer, for a continuous term beginning on the Effective Date
and ending on the third anniversary of the Effective Date hereof (the “Initial Term”). The Initial Term shall be extended
automatically for additional one-year periods (each a “Renewal Term”), on the same terms and conditions as set forth
in this Agreement (as may be modified from time to time, in writing, by the Parties), beginning on the third anniversary of the date
hereof, unless either Party gives the other Party written notice of such Party’s decision not to renew the terms of this Agreement
at least ninety (90) days prior to the end of the Initial Term or any Renewal Term. The Initial Term, together with all Renewal Terms,
are collectively referred to as the “Employment Term.” Notwithstanding the foregoing, either Party may terminate this
Agreement at any time prior to the expiration of the Employment Term under the terms and conditions described in Section 6.

 

3.          Duties.
The duties of Executive shall be those which are usually and customarily associated with the position of a President and CFO of a comparably-sized
company and the Executive will be expected to live within a 50-mile radius of Lincoln, Nebraska and work in the Employer’s Lincoln,
Nebraska office. Executive will have the duties, responsibilities and authorities as detailed in Exhibit A attached hereto
and incorporated herein, as well as such other reasonably related duties, responsibilities and authorities as may be specified by the
co-Chief Executive Officers (“co-CEOs”) of MHI, or any successor(s) to the co-CEOs. Executive shall report directly
to the co-CEOs of MHI for the performance of her duties. Executive shall devote substantially all of her working time, attention, skill
and reasonable best efforts to the performance of her duties hereunder in a manner that will faithfully and diligently further the business
and interests of MHI. During the Employment Term, Executive shall refrain from acting as an employee, employer, consultant, agent, principal,
partner, stockholder, officer, director, or in any other individual or representative capacity own, operate, control, assist, or participate
in any business that is in competition in any way with the Employer; provided, that this prohibition shall not preclude Executive from:
(i) serving as a member of the Board of Directors of one additional for-profit company, if and only if the company is not engaged
in the Business, does not constitute a conflict of interest and does not create an appearance of impropriety; (ii) engaging in charitable,
civic or other volunteer activities, or (iii) owning stock of any company whose shares are listed for trading over any public or
over-the-counter exchange if, and only if, (a) Executive does not own more than five percent (5%) of such shares of any such company,
and (b) Executive does not control such company, and (c) such ownership does not constitute a conflict of interest, create
an appearance of impropriety or otherwise violate any provision of applicable law. Executive acknowledges and agrees that Executive’s
employment relationship is solely with Employer, that Employer retains all rights and authority to control Executive’s activities
in carrying out the terms of this Agreement, and that the subsidiaries of MHI and its affiliates shall not be considered a joint employer
of Executive for any purposes under this Agreement or under any federal, state or local laws.

 

    5 

     

    

 

4.           Compensation
for Services. In consideration for the services rendered to Employer, Executive shall be compensated as follows:

 

A.          Base
Salary. During the Employment Term, Executive shall be compensated at the annualized rate of $300,000.00 per calendar year (“Base
Salary”). Executive’s Base Salary, subject to applicable withholding and authorized deductions, shall be paid in 24 equal
semi-monthly installments, in accordance with the usual and customary payroll practices of the Employer. The Parties may discuss renegotiation
of the Base Salary each calendar year based on periodic performance reviews, but Employer retains sole and absolute discretion to maintain
or modify the Base Salary.

 

B.           Bonus.
In addition to the Base Salary, during the Employment Term, Executive shall be eligible to receive an annual target bonus of 50% of the
Base Salary as in effect for such year (“Target Bonus”), and Executive’s actual annual bonus may range from
0% to 100% of the Base Salary, and will be determined based upon achievement of performance goals established by the Compensation Committee
of the Board (after conferring with the co-CEOS and the Executive) annually at or near the beginning of each calendar year during the
Employment Term (the “Annual Bonus”); provided that, it is understood that such performance goals shall be
a meaningful test of Executive’s and MHI’s performance. The determination (i) whether any Annual Bonus will be paid
by the Employer and (ii) if such Annual Bonus is to be paid by the Employer, whether the specified performance goals have been satisfied,
shall be made by MHI in its reasonable discretion. The Annual Bonus (if any) with respect to any calendar year shall be payable in the
following calendar year no later than the earlier of (i) 30 days after the date on which audited financial statements covering such
calendar year performance period become available to the Employer, or (ii) June 30 of the following calendar year. For the
2021 performance year, Executive will be paid a minimum bonus of $50,000.00, which becomes payable upon successful filing of a Form 10-K
with the SEC in March 2022. If Executive is not employed by Employer at the end of a calendar year, and except as otherwise provided
in Sections 9(B) or (C) below with respect to severance, a pro rata Target Bonus based on the period of employment may be paid
at the sole discretion of MHI; provided, that, a pro rata Target Bonus shall be paid to Executive (or to the heirs or estate of
Executive) if Executive’s employment ceases as a result of Executive’s death or Employer’s termination of Executive’s
employment due to Permanent Disability (as hereinafter defined). The pro rata Target Bonus, if any, shall be paid to Executive on the
date on which the Target Bonus would have been paid to Executive for such calendar year, but for Executive’s termination.

 

C.          Additional
Compensation. In addition to any other compensation set forth in this Section 4, during the Employment Term, promptly following
the Effective Date, Executive shall receive stock options to purchase 43,000 shares of common stock as of the Effective Date. Any such
grant shall be subject to the terms and conditions set forth in the MHI 2020 Long-Term Incentive Plan, as in effect and as amended from
time to time (the “Incentive Plan”), together with the Stock Option Agreement between MHI and Executive. The stock
options shall have a strike price of the greater of either $41.25 or the fair market value as of the date of the grant, which shall be
September 8, 2021, and shall expire 10 years from the date of grant. The stock options will vest in equal installments 60 days after
each of the first seven anniversaries of the date of grant, subject (except as otherwise provided herein or in the Incentive Plan) to
Executive’s continuous employment with the Employer through the applicable vesting date, or as otherwise provided in Section 9
below. Additional equity grants to Executive may be made by MHI in its reasonable discretion.

 

    6 

     

    

 

D.          Benefits.
During Executive’s employment with Employer, subject to the provision in the final sentence of this Section 4(D), Executive
shall receive the following benefits (together, the “Other Benefits”):

 

(i)           Employer
shall pay the full premium required to provide the Executive and Executive’s spouse and family with coverage under Employer’s
group health and dental plan as per current practice with comparable executives employed by MHI.

 

(ii)            Executive
shall be eligible to participate in all leave policies and “fringe” benefit programs, including, but not limited to, 1 week
sick leave, 4 weeks of personal leave, insurance programs and/or a 401(k) plan, as and to the extent the same are from time to time
made available to employees of Employer.

 

Anything herein to the contrary
notwithstanding, however, the Other Benefits and the terms and conditions thereof may be hereafter modified or terminated from time to
time by MHI consistent with other similarly situated employees and without amending this Agreement, and the Executive’s eligibility,
participation and benefit entitlement for each of the foregoing policies, plans, programs or Other Benefits shall be subject to all of
the terms and conditions of each such policy, plan or program and any third party contracts, agreements or policies of insurance which
may be applicable thereto.

 

E.            Continuation
of Salary During Illness. If Executive shall become ill or temporarily disabled and shall be absent from work by reason thereof, Employer
shall continue Executive’s semi-monthly installments of her Base Salary during said period of illness or disability for up to a
maximum of six (6) months or such lesser time as required to permit Executive to qualify for any long disability income insurance
maintained by Executive.

 

F.           Clawback
Provisions. Notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation, or any other
compensation, paid to Executive pursuant to this Agreement or any other agreement or arrangement with MHI which is subject to recovery
under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback, limited
to the net after-tax repayment, as may be required to be made pursuant to the applicable “recovery” provision and to such
law, government regulation or stock exchange listing requirement (or any policy adopted by MHI pursuant to any such law, government regulation
or stock exchange listing requirement).

 

5.           Expense
Reimbursement. Employer agrees to reimburse Executive, in accordance with Employer’s usual and customary practices, for all
other ordinary and necessary business expenses which are reasonably and necessarily incurred by the Executive in the course of performing
Executive’s duties on Employer’s behalf under this Agreement. Employer will provide relocation support and home purchase
assistance up to $50,000, adjusted for tax impact. This will be subject to pro rata repayment, if Executive’s employment with Company
is terminated under Section 6(C) or Executive resigns without Good Reason, on or before December 31, 2023.

 

6.           Termination.
Nothing in this Agreement is intended to provide, nor shall this Agreement provide, Executive with any contractual rights to employment
for any specified period of time. Executive and Employer acknowledge and agree that the employment relationship between Executive and
Employer is and shall remain strictly “at-will” during the Employment Term. This means that either Executive or Employer
may, at any time, for any reason or no reason, terminate the employment relationship between Executive and Employer, including any time
before the end of the Initial Term and any Renewal Term(s) noted in Section 2. In addition, and without limiting the foregoing,
this Agreement may be terminated as follows:

 

A.          Death.
This Agreement shall immediately terminate upon the event of Executive’s death.

 

B.          Disability.
Subject to Section 4(D) with respect to applicable leave policies, this Agreement shall immediately terminate in the event
Executive is Permanently Disabled, has exhausted all available leave, and is unable to return to work and perform the essential functions
of her employment. “Permanently Disabled” shall mean a physical or mental impairment rendering Executive substantially
unable to carry out Executive’s then currently assigned day-to-day functions as President and CFO for any period of six (6) consecutive
months. Any dispute as to whether Executive is Permanently Disabled, and the date on which such incapacity commenced, shall be resolved
by MHI with the assistance of a qualified physician mutually selected by the Parties, no later than 30 days after the Parties dispute
whether Executive is Permanently Disabled, unless the Parties mutually agree in writing to extend this deadline. The decision of MHI
shall be final and binding upon Executive and Employer. If Executive does not (i) cooperate in selecting the physician, (ii) submit
to examination by the physician mutually selected by the Parties within the aforementioned 30-day deadline, or (iii) provide access
to needed information upon which such determination can be made, then MHI shall have no continued obligation to consult with such physician
and will have the authority to determine whether Executive is Permanently Disabled on its own.

 

    7 

     

    

 

C.          Involuntary
Termination for Good Cause. Employer may terminate Executive’s employment at any time for Good Cause. “Good Cause”
shall be deemed to exist if, and only if:

 

(i)           Executive
willfully engages in acts or omissions determined by Employer to constitute fraud, breach of fiduciary duty or intentional wrongdoing
or malfeasance, including without limitation knowing falsification of the financial books or records of Employer (or its subsidiaries
or affiliates), embezzlement of funds from Employer (or its subsidiaries or affiliates) or other similar fraud; provided, however,
that a breach of fiduciary duty shall not be deemed to occur or exist as a result of any business decision made by Executive that is protected
by the “business judgment rule” as adopted by courts applying the General Corporation Law of the State of Delaware;

 

(ii)          Executive
is convicted of, or enters a plea of guilty or nolo contendere to charges of, any criminal violation involving fraud, theft or
dishonesty;

 

(iii)         Executive
is convicted of, or enters a plea of guilty or nolo contendere to charges of, any non-vehicular felony which has or is substantially
likely to have a material adverse effect on Executive’s ability to carry out Executive’s duties under this Agreement or on
the reputation or activities of Employer (or its subsidiaries or affiliates);

 

(iv)         Executive
habitually abuses alcohol, illegal drugs or controlled substances or non-prescribed prescription medicine, and such abuse materially and
adversely interferes with the performance of Executive’s duties and responsibilities to Employer, and such acts remain uncured for
more than 30 days following receipt by Executive of written notice from the Employer specifying the nature of such acts demanding cure
thereof;

 

(v)         Executive
materially breaches the terms of any agreement between Executive and Employer (or its subsidiaries or affiliates) relating to Executive’s
employment, materially fails to adhere to significant policies of Employer applicable to all employees, including, without limitation,
policies prohibiting sexual harassment in the workplace, or materially fails to satisfy the conditions and requirements of Executive’s
employment with the Employer (or its subsidiaries or affiliates), and such breach or failure remains uncured for more than 30 days following
receipt by Executive of written notice from Employer specifying the nature of such breach or failure and demanding cure thereof;

 

(vi)         Executive
engages in acts or omissions constituting gross negligence by Executive in the performance (or non-performance) of Executive’s duties
hereunder, and such act or omission remains uncured for more than 30 days following receipt by Executive of written notice from Employer
specifying the nature of such act or omission and demanding cure thereof; or

 

(vii)        Executive
materially fails in the performance of Executive’s duties and/or responsibilities on behalf of Employer, and such failure remains
uncured for more than 30 days following receipt by Executive of written notice from Employer specifying the nature of the failure and
demanding cure thereof.

 

    8 

     

    

 

7.          Effect
of Termination. In the event Executive’s employment is terminated pursuant to Section 6(A), 6(B) or 6(C) above,
Executive shall only be entitled to receive that portion of Executive’s Base Salary and Target Bonus which has been earned but
remains unpaid up to the date of such termination, in addition to Other Benefits through the date of such termination and the reimbursement
of any expenses as provided in Section 5. For purposes of clarity, Executive shall not be entitled to any remaining unpaid Base
Salary following the date of such termination. In the event Executive’s employment is terminated by Employer for reasons other
than those provided in Section 6(A), 6(B) or 6(C), such as non-renewal of agreement by the Employer as noted in Section 2,
Executive shall be entitled to the amounts set forth in Section 9 below subject to the terms and conditions contained therein.

 

8.           Resignation;
Effect. In the event Executive resigns other than for Good Reason (as defined below), Executive (i) shall be entitled to receive
that portion of Executive’s Base Salary which has been earned but remains unpaid up to the date of such termination, in addition
to Other Benefits through the date of such termination and the reimbursement of any expenses as provided in Section 5, and (ii) shall
continue to receive Executive’s Base Salary for up to a period of twelve (12) months after the effective date of Executive’s
resignation, provided that, Executive signs and does not revoke a Release as defined in Section 9(B) below and remains
in compliance with Section 12 below with respect to non-competition. Executive agrees that Executive will immediately report to Employer
any offer of employment accepted by Executive within twelve (12) months of Executive’s resignation, including the date such employment
is to commence, for the purpose of allowing Employer to determine compliance with Section 12 of this Agreement. Employer’s
obligation to pay or continue payment of Base Salary shall cease in the event Executive is in breach of Section 12 of this Agreement.
Alternatively, Employer may at any time during the 12-month non-competition period contemplated by Section 12 immediately terminate
its continuing obligation to pay or continue payment of the Base Salary if Employer releases Executive from Executive’s non-competition
obligations under Section 12 by written notice to Executive. If the Executive resigns with Good Reason, Executive shall be entitled
to the amounts set forth in Section 9 below subject to the terms and conditions contained therein. For purposes of this Agreement,
 “Good Reason” shall mean:

 

(i)           the
material diminution of any duties, responsibilities, and authorities inconsistent in any respect with Executive’s position as a
President and CFO of a comparably sized company (including status, offices, titles and reporting requirements), authority, duties or responsibilities
as contemplated by Sections 1 and 3 of this Agreement, excluding for this purpose an isolated, insubstantial and inadvertent action not
taken in bad faith and which is remedied by MHI within thirty (30) days after receipt of notice thereof given by Executive;

 

(ii)          any
failure by MHI to comply with any of the provisions of Section 4 of this Agreement, other than an isolated, insubstantial and inadvertent
failure not occurring in bad faith and which is remedied by MHI within 30 days after receipt of written notice thereof given by Executive.
For clarification purposes, MHI’s failure to grant Executive the stock options described in Section 4(C)(i) and enter
into the Stock Option Agreement within six (6) months following the Effective Date shall constitute Good Reason under this Agreement
provided that, MHI shall be entitled to the cure period described in the preceding sentence; or

 

(iii)         MHI
materially breaches the terms of any agreement between Executive and Employer relating to Executive’s employment, or materially
fails to satisfy the conditions and requirements of this Agreement, and such breach or failure by its nature is incapable of being cured,
or such breach or failure remains uncured for more than 30 days following receipt by Employer of written notice from Executive specifying
the nature of the breach or failure and demanding the cure thereof.

 

Notwithstanding the foregoing,
Executive shall not have Good Reason to terminate Executive’s employment unless the event giving rise to Good Reason is not fully
remedied within thirty (30) days after receipt by Employer of a written notice from Executive of such event, specifying in detail the
reason or reasons constituting Good Reason, which written notice must be provided within ninety (90) days after the initial occurrence
of such event. A termination for Good Reason cannot occur later than one-hundred and twenty (120) days following the initial occurrence
of the applicable event. For the purposes of this Agreement, termination by Executive “without Good Reason” shall mean
termination by Executive of Executive’s employment for any reasons other than a termination for Good Reason.

 

    9 

     

    

 

9.           Severance.

 

(A)         If
Employer terminates Executive’s employment under this Agreement for reasons other than those provided in Sections 6(A), 6(B) and
6(C), or if Executive resigns and terminates this Agreement for Good Reason as defined in Section 8 (each a “Qualifying
Termination”), Employer shall pay to Executive that portion of Executive’s Base Salary and Target Bonus which has been
earned up to the date of such termination, in addition to Other Benefits through the date of such termination and the reimbursement of
any expenses as provided in Section 5.

 

(B)          In
connection with a Qualifying Termination that occurs at any time , and provided Executive signs and does not revoke as may be permitted
by law a general release of claims in a form similar to that attached as Exhibit C (the “Release”), Employer shall
(i) pay to Executive on a quarterly basis following the date of such termination an amount equal to the pro rata amount of (a) the
Base Salary for each quarter of the Severance Period (as hereinafter defined) commencing on the first payroll date falling after the Release
becomes effective; and (b) the Target Bonus for each quarter of the twelve (12) month period; (ii) continued vesting of stock
options and other equity awards granted to Executive pursuant to Section 4(C)(i) and (ii) above through the end of the
Severance Period; and (iii) subject to Executive’s timely election of continuation coverage under COBRA, pay to Executive a
lump sum amount equal to the total monthly premiums that would be necessary to continue Executive’s and Executive’s eligible
dependents’ participation in Employer’s group health plan (to the extent permitted under applicable law and the terms of such
plan) which covers Executive (and Executive’s eligible dependents) on the date of Executive’s termination for a period of
twelve (12) months/during the Severance Period. All amounts payable under this Section 9(B) shall be treated as taxable payments.
The term “Severance Period” shall mean a period extending from the date of termination and continuing through twelve
(12) months after the date of termination.

 

(C)         The
payments and benefits provided for in Sections 8 or 9(B) are conditioned on Executive entering into and not revoking the Release
on or before the sixtieth (60th) day following the date on which Executive’s termination of employment becomes effective.
Employer shall be deemed to execute the Release on the date that Executive executes the Release. If Executive fails to execute without
revocation the Release, she shall be entitled to the benefits set forth in Section 9(A) only and no other benefits under Sections
8 or 9(B). The installments of severance payable under Section 8 shall commence with the first payroll period following the date
on which the Release becomes enforceable and irrevocable. The installments of severance provided under Section 9(B) shall commence
in the quarter ending in which the Release becomes enforceable and irrevocable. If, however, the sixty (60) day period in which the Release
must become enforceable and irrevocable begins in one year and ends in the following year, Employer shall commence payment of the severance
installments in the following year. The first installment of the severance shall include all amounts that would otherwise have been paid
to Executive between Executive’s termination date and Executive’s receipt of the first installment, assuming the first installment
would otherwise have been paid at the end of the quarter in which the Executive’s employment terminates.

 

(D)         Employer
and Executive agree that Executive shall have no duty to mitigate Executive’s losses or obtain other employment for the purposes
of this Section. If Executive obtains other employment, it shall not affect Executive’s right to payment under this Section.

 

10.         Indemnification;
Directors’ and Officers’ Liability Insurance. As and to the extent provided in MHI’s bylaws, Executive will be
entitled to the indemnification provided to other executive officers and directors of MHI. In addition, MHI agrees to include Executive
as a covered person on a directors’ and officers’ liability insurance policy or policies covering Executive to the same extent
that MHI provides such coverage for its other executive officers and directors.

 

11.         Proprietary
Matters Agreement. Prior to or concurrently with the execution of this Agreement, Executive has signed Employer’s Proprietary
Matters Agreement attached hereto as Exhibit B, the terms of which are expressly incorporated herein. The termination of this Agreement
or the termination of Executive’s employment with Employer for any reason shall in no way diminish Executive’s continuing
obligations under the Proprietary Matters Agreement signed by Executive.

 

    10 

     

    

 

12.         Non-Competition.
During Executive’s employment with Employer and for a period of twelve (12) months thereafter, the Executive agrees that Executive
shall not, within the United States, directly or indirectly, whether as an officer, director, stockholder, partner, member, employee,
proprietor, associate, representative, investor or consultant, or in any capacity whatsoever, engage in, become financially interested
in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity that is engaged
in the Business; provided, however, that the foregoing restriction shall not prevent Executive from owning not more than two percent
(2%) of the outstanding shares in any publicly traded corporation or from having an interest in or being employed by an enterprise having
multiple business segments, divisions or product lines one or more of which is in competition with Employer, provided that Executive
is not employed by, and does not render any services or support to or otherwise assist, the division or business segment or product line
of such enterprise that is in competition with Employer.

 

Executive agrees and acknowledges
that the time limitation and scope of activity to be restrained by the restrictions in this Section, combined with the geographic scope,
are reasonable. Executive also acknowledges and agrees that this Section is reasonably necessary for the protection of Employer’s
Confidential Information and trade secrets, is supported by adequate consideration, and provides a reasonable way of protecting the business
value of the Employer.

 

13.         Remedies
for Breach of Non-Competition Covenant.

 

A.          Executive
acknowledges that, because Executive’s services are personal and unique and because Executive shall have access to and become acquainted
with the Confidential Information of Employer, the damages that would be suffered by Employer as a result of the breach of the provisions
of this Agreement contained in Section 12 above may not be calculable, and that an award of a monetary judgment to Employer for such
a breach would be an inadequate remedy. Consequently, Employer shall have the right, in addition to any other rights it may have under
this Agreement or elsewhere at law, to obtain injunctive relief in any court of competent jurisdiction to restrain any breach or threatened
breach hereof or otherwise to specifically enforce any of the provisions of this Agreement.

 

B.           The
covenants made by Executive in Section 12 above shall be construed as agreements independent of any other provisions of this Agreement
(with the exception of Section 11 and the Proprietary Matters Agreement), and the existence of any claim or cause of action of the
Executive against Employer, whether predicted on this Agreement or otherwise, shall not constitute a defense to the enforcement by MHI
of these covenants.

 

C.           If
a court shall determine that any provision of (or portion of a provision of) Section 12 of this Agreement is unenforceable in accordance
with its terms, either because it extends for too long a period of time or over too great a range of activities or in too broad a geographic
area or for any other reason, it shall nonetheless be enforced on such terms as the court determines are equitable and legally enforceable.

 

14.         Severability.
Invalidity of any provision of this Agreement shall not render invalid any of the other provisions of this Agreement, and if any part
of this Agreement should be determined to be unlawful, unenforceable or against public policy, the remaining parts shall continue to be
fully effective and enforceable.

 

15.        Miscellaneous
Provisions.

 

A.          Successor
and Assigns. This Agreement is personal in nature and Executive may not assign or delegate any rights or obligations hereunder without
first obtaining the express written consent of Employer. The rights, benefits, and obligations of Employer under this Agreement and all
covenants and agreements pertaining thereto hereunder shall be assignable by Employer. Further, this Agreement shall inure to the benefit
of and be enforceable by or against the Parties’ successors and assigns, provided Employer shall remain liable to Executive for
the performance of all obligations to be performed by it hereunder.

 

B.           Entire
Agreement. This Agreement, together with the Proprietary Matters Agreement, Incentive Plan and Stock Option Agreement, contain
the entire agreement of the parties with respect to the subject matter hereof and supersede and replace all prior agreements or understandings
and all negotiations, discussions, arrangements, and understandings with respect thereto. For purposes of clarification and the avoidance
of doubt, Executive acknowledges and agrees that the terms and provisions contained with the Proprietary Matters Agreement signed by Executive
and attached as Exhibit B shall remain in full force and effect and shall survive following Executive’s employment with Employer.

 

    11 

     

    

 

C.          Binding
Effect. This Agreement shall be binding upon the Parties and their respective heirs, personal representatives, administrators, trustees,
successors, and permitted assigns.

 

D.          Amendment
or Modification. No amendment or modification of this Agreement shall be binding unless executed in writing by the Parties hereto.

 

E.           Governing
Law. Employer and Executive agree that this Agreement shall be governed by and construed according to the laws of the State of Delaware.

 

F.           Interpretations.
Any uncertainty or ambiguity existing herein shall not be interpreted against either Party because such Party prepared any portion of
this Agreement but shall be interpreted according to the application of rules of interpretation of contracts generally. The headings
used in this Agreement are inserted for convenience and reference only and are not intended to be an integral part of or to affect the
meaning or interpretation of this Agreement.

 

G.          Notices.
Any notice required to be given in writing by any Party to this Agreement may be delivered personally or by certified mail. Any such notice
directed to Employer shall be addressed to Employer at 2900 South 70th Street, Suite 400, Lincoln, Nebraska 68510, Attention:
Secretary, General Counsel; or to such other address as the Employer may from time to time designate in writing to Executive. Any notice
addressed to Executive shall be addressed to Executive’s personal residence at 494 E. Burr Pond Road, Brandon, Vermont 05733 or
to such other address as Executive may from time to time designate in writing to Employer.

 

H.          Survival.
Anything herein to the contrary notwithstanding, the rights and obligations of the Parties hereunder which by their terms contemplate
or require performance or obligations which extend beyond or occur after the termination of this Agreement (specifically including, but
not limited to, the payments to Executive provided for in Sections 7, 8 and 9, the indemnification of Executive provided for in Section 10,
the non-competition provisions of Section 12 and the Proprietary Matters Agreement signed by Executive) shall survive termination
of this Agreement and shall be and remain fully enforceable as between the Parties in accordance with their terms.

 

I.            Voluntary
Execution; Conflict Waiver. Executive and Employer are signing this Agreement knowingly and voluntarily. Executive and Employer have
been given the opportunity to consult with independent counsel of their choice regarding their rights under this Agreement.

 

J.           Signatures.
This Agreement may be executed in counterparts, both of which shall be one and the same Agreement.

 

K.          Section 409A
Compliance.

 

(i)           To
the extent that any of the payments or benefits provided for in Section 8 or 9(B) are deemed to constitute non-qualified deferred
compensation benefits subject to Section 409A of the United States Internal Revenue Code (the “Code”), the following
interpretations apply to Section 8 or 9(B):

 

(a)         Any
termination of Executive’s employment triggering payment of benefits under Section 8 or 9(B) must constitute a “separation
from service” within the meaning of Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) for interpreting
a separation from service before distribution of such benefits can commence. To the extent that the termination of Executive’s employment
does not constitute a separation of service, any benefits payable under Section 8 or 9(B) that constitute deferred compensation
under Section 409A of the Code shall be delayed until after the date of a subsequent event constituting a separation of service.
For purposes of clarification, this Section shall not cause any forfeiture of benefits on the Executive’s part but shall only
act as a delay until such time as a separation from service occurs.

 

    12 

     

    

 

(b)          If
Executive is a “specified employee” (as that term is used in Section 409A of the Code and regulations and other guidance
issued thereunder) on the date Executive’s separation from service becomes effective, any benefits payable under Section 8
or 9(B) (if any) that constitute non-qualified deferred compensation under Section 409A of the Code shall be delayed until the
earlier of (1) the business day following the six-month anniversary of the date Executive’s separation from service becomes
effective, and (2) the date of Executive’s death, but only to the extent necessary to avoid penalties under Section 409A
of the Code. On the earlier of (1) the business day following the six-month anniversary of the date Executive’s separation
from service becomes effective, and (2) Executive’s death, Employer shall pay Executive in a lump sum the aggregate value of
the non-qualified deferred compensation that Employer otherwise would have paid Executive prior to that date under Section 8 or 9(B) of
this Agreement.

 

(ii)          It
is intended that each installment of the payments and benefits provided under Section 8 or 9(B) be treated as a separate “payment”
for purposes of Section 409A of the Code. In particular, the installment severance payments set forth in Section 8 or 9(B) of
this Agreement shall be divided into two portions. The first portion will equal that number of installments commencing on the first payment
date set forth in Section 8 or 9(B) that are in the aggregate less than two times the applicable compensation limit under Section 401(a)(17)
of the Code for the year in which the termination of Executive’s employment occurs (provided the termination of Executive’s
employment is also a separation from service) is payable in accordance with Treas. Reg. §1.409A-1(b)(9)(iii) as an involuntary
separation plan. The second portion will equal the remainder of the installments and shall be paid in accordance with Sections 15.K.i
above.

 

(iii)        Neither
Employer nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent
specifically permitted or required by Section 409A of the Code.

 

(iv)         It
is the intention of both Employer and Executive that the benefits and rights to which Executive could be entitled pursuant to this Agreement
comply with Section 409A of the Code and the Treasury Regulations and other guidance promulgated or issued thereunder, to the extent
that the requirements of Section 409A are applicable thereto, and the provisions of this Agreement shall be construed in a manner
consistent with that intention. If Executive or Employer believes, at any time, that any such benefit or right that is subject to Section 409A
does not so comply, it shall promptly advise the other and shall negotiate reasonably and in good faith to amend the terms of such benefits
and rights such that they comply with Section 409A (with the most limited possible economic effect on Executive and on Employer)
to the extent allowed by applicable law. To the extent that any payment provided to Executive pursuant to this Agreement is subject to
adverse tax consequences under Section 409A (solely as a result of Employer’s action or inaction with respect to such payment),
Employer will make such additional payments to Executive (the “409A Gross Up Payments”) as are necessary to provide
Executive with sufficient funds to pay the additional taxes, interest, and penalties imposed by Section 409A (collectively, the “409A
Tax”), as well as any additional taxes, including but not limited to additional 409A Tax, attributable to or resulting from
the payment of the 409A Gross Up Payments, with the end result that Executive will be in the same position with respect to Executive’s
tax liability as Executive would have been in if no 409A Tax had ever been imposed. Employer will make any payments required by this
paragraph no later than the last day of Executive’s taxable year next following Executive’s taxable year in which the 409A
Tax is remitted to the taxing authority. In no other event whatsoever will Employer be liable for additional tax, interest or penalty
that may be imposed on Executive by Section 409A or damages for any payments or benefits that fail to comply with Section 409A.

 

    13 

     

    

 

L.            Excess
Parachute Payments.

 

(i)          Notwithstanding
anything in this Agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer to Executive or
for Executive’s benefit pursuant to the terms of this Agreement or otherwise (“Covered Payments”) are determined
to constitute “excess parachute payments” within the meaning of Section 280G of the Code and would, but for this Section 15(L) be
subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed
by state or local law or any interest or penalties with respect to such taxes (collectively, the “Excise Tax”), then
the Covered Payments shall either (a) be paid in full or (b) be reduced (but not below zero) to the minimum extent necessary
to ensure that no portion of the Covered Payments is subject to the Excise Tax, whichever of (a) or (b) maximizes the after-tax
results applicable to Executive. All determinations required to be made under this Section 15(L), including whether a payment would
result in an “excess parachute payment” and the assumptions utilized in arriving at such determination, shall be made in writing
by an accounting firm selected by Employer, which writings shall be shared with Executive.

 

(ii)          If
a reduction in the Covered Payments is required by the foregoing provisions of this Section 15(L), the reduction shall occur in the
following order: (i) reduction of cash payments for which the full amount is treated as a parachute payment; (ii) cancellation
of accelerated vesting (or, if necessary, payment) of cash awards for which the full amount is not treated as a parachute payment; (iii) cancellation
of any accelerated vesting of equity awards; and (iv) reduction of any continued employee benefits. In selecting the equity awards
(if any), for which vesting will be reduced under clause (iii) of the preceding sentence, awards shall be selected in a manner that
maximizes the after-tax aggregate amount of Covered Payments, provided that if (and only if) necessary in order to avoid the imposition
of an additional tax under Section 409A of the Code, awards instead shall be selected in the reverse order of the date of
grant. In no event shall Executive have any discretion with respect to the ordering of payment reductions.

 

(iii)         If
the Covered Payments to Executive are reduced in accordance with this Section 15(L), as a result of the uncertainty in the application
of Section 4999 of the Code at the time of the initial reduction under Section 15(L), it is possible that Covered Payments to
the Executive which will not have been made by the Employer should have been made (“Underpayment”) or that Covered
Payments to Executive which were made should not have been made (“Overpayment”). If an Underpayment has occurred, the
amount of any such Underpayment shall be promptly paid by te Employer to or for the benefit of Executive. In the event of an Overpayment,
then Executive shall promptly repay to Employer the amount of any such Overpayment together with interest on such amount (at the same
rate as is applied to determine the present value of payments under Section 280G of the Code or any successor thereto), from the
date the reimbursable payment was received by Executive to the date the same is repaid to Employer.

 

[Remainder of Page Intentionally Left
Blank – Signature Page Follows]

 

    14 

     

    

 

IN WITNESS WHEREOF, Employer
and Executive have caused this Agreement to be signed with the intent it be effective as of the Effective Date, fully intending the same
to be binding upon themselves and their respective heirs, personal representatives, trustees, successors, receivers and assigns.

 

	 	EXECUTIVE
	 	 
	 	 
	 	By:	 /s/ Georgette C. Nicholas
	 	 	Georgette C. Nicholas
	 	 
	 	MIDWEST HOLDING INC.
	 	 
	 	 
	 	By: 	/s/ Mike Minnich
	 	 	Mike Minnich
	 	 	Co-CEO

 

    15 

     

    

 

Exhibit A

Duties, Responsibilities and Authorities

 

As President:

 

		-	Working with the co-CEOs in setting and executing on the strategic direction of the company including the prioritization of its resources

		-	Overseeing the Lincoln, NE office. Direct reports shall include:

		o	Finance, [Investment Operations], [Policy Administration], HR, IT, Legal and compliance

 

As CFO:

 

		-	Providing leadership, direction and management of the finance and accounting team

		-	Providing strategic recommendations to the co-CEOs and members of the executive management team

		-	Managing the processes for financial forecasting and budgets, and overseeing the preparation of all financial reporting

		-	Advising on long-term business and financial planning

		-	Establishing and developing relations with external partners and investors

		-	Reviewing all formal finance, HR and IT related procedures

		-	Interfacing directly with the board and audit committee

 

    16 

     

    

 

Exhibit B

 

Proprietary Matters Agreement

 

    17 

     

    

 

PROPRIETARY MATTERS AGREEMENT

 

As a condition of my relationship
with Midwest Holding Inc., its affiliates, subsidiaries, and/or its successors or assigns (collectively, the “Company”),
and in consideration of the Confidential Information (as defined below) now and hereafter provided to me by the Company, and for other
good and valuable consideration (including my relationship and/or continued relationship with the Company), the receipt and sufficiency
of which are hereby acknowledged, I hereby agree as follows:

 

		1.	GENERAL. During my employment with the Company under the Employment

 

Agreement, dated September 8, 2021 with the
Company (the “Employment Term”), I agree

 

a.            not
to engage, directly or indirectly, in any business, investment or activity that interferes or is contrary to the interests of the Company

 

b.            to
disclose current material outside business activities in the insurance and/or asset management industries and update the Company on any
future material outside business activities in the insurance and/or asset management industries; and

 

c.            to
comply with all laws and regulations and all Company policies.

 

I accept, acknowledge and
agree that I received additional consideration pursuant to the terms and conditions of a related agreement I entered into with the Company.

 

		2.	CONFIDENTIAL INFORMATION.

 

a.            COMPANY
INFORMATION. Except as set forth herein, I hereby agree, at all times during and following my relationship with the Company during
the Restricted Period (defined below), to hold in strictest confidence and not to use, except for the benefit of the Company and as required
in the ordinary course of performing my duties, or to disclose to any person, firm or corporation without written authorization of the
Company, any Confidential Information of the Company. I understand that “Confidential Information” means any and all information
furnished by the Company before or after the date of this Agreement, orally, in writing, or gathered by inspection and regardless of whether
or not specifically marked as “Confidential,” including, without limitation, information relating to the Company’s past,
present, or future research, development or business affairs such as trade secrets, inventions (whether or not patentable), software,
software and technology architecture, networks, business methodologies, facilities, billing records, policies, financial and operational
information, contracts, officer, director and shareholder information, suppliers, client lists, marketing or sales prospects, projected
projects and all copies, reproductions, notes, analyses, compilations, studies, interpretations, summaries and other documents whether
or not prepared by me. I also understand that “Confidential Information” does not include any of the foregoing items which
have become publicly known or generally known in the industry and made generally available through no wrongful act of mine or of others
who were under confidentiality obligations with respect to the item or items involved. Notwithstanding anything to the contrary in this
Agreement, Confidential Information shall not include any information in my possession or known to me prior to my employment with the
Company, my professional knowledge and skill, or my contact lists, whether in electronic or paper form (e.g. rolodex, Outlook contacts, etc.).
To the extent I become a shareholder or an option holder of the Company, I agree that all information distributed to me as a shareholder
or option holder will be treated as Confidential Information, except as otherwise provided herein. I agree I shall not use any Confidential
Information in any manner which may reasonably be expected to materially injure or cause loss to the Company, whether directly or indirectly.

 

b.            FORMER
EMPLOYER INFORMATION. I hereby agree that I will not, during my relationship with the Company, improperly use or disclose any proprietary
information or trade secrets of any former or concurrent employer or other person or entity for whom I have worked in the past, for whom
I am now working or for whom I may work during the term of my relationship with the Company, and that I will not bring onto the premises
of the Company any unpublished document or proprietary information or property belonging to any such employer, person or entity unless
consented to in writing by such employer, person or entity. I represent and warrant that, except as set forth on Exhibit 1, I
am not subject to any agreement, understanding or other duty (whether pursuant to any noncompetition, non-solicitation or confidentiality
agreement or otherwise) that would in any way restrict or hinder the performance of my duties to the Company.

 

    1 

     

    

 

c.            THIRD
PARTY INFORMATION. I recognize that the Company has received, and in the future will receive, the confidential or proprietary information
of third parties subject to a duty of the Company to maintain the confidentiality of such information and to use it only for certain limited
purposes. I hereby agree to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to
any person, firm, or corporation or to use it except as necessary in carrying out my work for the Company in accordance with the Company’s
agreements or other arrangements with any such third parties.

 

3.             INVENTIONS.

 

a.            INVENTIONS
RETAINED AND LICENSED. I have attached hereto, as Exhibit 1, a list describing all inventions, original works of authorship,
developments, improvements, and trade secrets which were made by me prior to my relationship with the Company, including those conceived,
developed or reduced to practice prior to execution of this Agreement, or which are owned by me (collectively referred to herein as “Prior
Inventions”), or, if no such list is attached, I represent that there are no such Prior Inventions. If in the course of my
relationship with the Company I incorporate into a Company product, process, service or machine a Prior Invention owned by me or in which
I have an interest, but which is not an Assigned Invention (defined below), the Company is hereby granted a nonexclusive, transferable,
royalty-free, fully paid, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part
of or in connection with such product, process or machine.

 

b.            ASSIGNMENT
OF INVENTIONS. I hereby agree that I have made or will promptly make full written disclosure to the Company of all of my right, title,
and interest in and to any and all inventions, original works of authorship, developments, concepts, improvements, designs, “know
how,” discoveries, ideas, trademarks or trade secrets, whether or not patentable or registrable under copyright, trademark, or similar
laws, which I solely or jointly have conceived, developed or reduced to practice prior to the date hereof, conceive, develop or reduce
to practice, or cause to be conceived or developed or reduced to practice (collectively, “Inventions”), during my relationship
with the Company (collectively, “Assigned Inventions”). To the extent permitted by applicable law, I hereby assign the
Assigned Inventions to the Company. For the purposes of this paragraph, Inventions shall not include inventions that I develop entirely
on my own time without using the Company’s equipment, supplies, facilities, or Confidential Information, except for those Inventions
that either (i) relate at the time of conception or reduction to practice of the Invention, to the Company’s business or actual,
anticipated or reasonably foreseeable research or development of the Company or to any customer or supplier of the Company’s business,
or (ii) result from any work performed by me for the Company. I understand and agree that the decision whether or not to commercialize
or market any Assigned Invention is within the Company’s sole discretion and for the Company’s sole benefit and that no royalty
will be due to me as a result of the Company’s efforts to commercialize or market any such Assigned Invention.

 

c.            MAINTENANCE
OF RECORDS. I hereby agree to keep and maintain adequate and current written records of all Inventions made by me during the term
of my relationship with the Company. The records will be in the form of notes, sketches, drawings, whether in electronic or hardcopy form,
and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company
at all times.

 

d.            FURTHER
ASSURANCES. I hereby agree to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the
Company’s rights in the Assigned Inventions and any copyrights, patents, trademarks, mask work rights or other intellectual property
rights relating thereto in any and all countries, including the disclosure to the Company of all pertinent information and data with respect
thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem
necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, and its successors, assigns,
and nominees, the sole and exclusive rights, title and interest in and to such Assigned Inventions, and any copyrights, patents, mask
work rights or other intellectual property rights relating thereto. I further agree that my obligation to execute or cause to be executed,
when it is in my power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company
is unable because of my mental or physical incapacity, death, absence, lack of cooperation or any other reason to secure my signature
to apply for or to pursue any application for any United States or foreign patents or copyright registrations covering Assigned Inventions,
then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney-in-fact,
to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further
the prosecution and issuance of letters patent or copyright registrations thereon with the same legal force and effect as if executed
by me.

 

    2 

     

    

 

4.             COMPANY
PROPERTY; RETURN OF COMPANY PROPERTY. I agree that during my relationship with the Company I shall not make, use or permit to be used
any Company Property otherwise than for the benefit of the Company. The term “Company Property” shall include all notes, memoranda,
reports, lists, records, drawings, sketches, specifications, software programs, software code, data, computers, cellular telephones, pagers,
credit and/or calling cards, keys, access cards, documentation or other materials of any nature and in any form, whether written, printed,
electronic or in digital format or otherwise, relating to any matter within the scope of the business of the Company or concerning any
of its dealings or affairs and any other Company Property in my possession, custody or control. I acknowledge and agree that all Company
Property shall be and remain the sole and exclusive property of the Company. I hereby agree that, at the time of ceasing to work with
the Company, I will immediately deliver to the Company (and will not keep in my possession, recreate or deliver to anyone else) any
and all Company Property, Confidential Information, devices, equipment, other documents or property, or reproductions in any medium of
any aforementioned items developed by me or received by me pursuant to my relationship with the Company or otherwise belonging to the
Company, or its successors or assigns. I further agree that I shall not, after the termination of my relationship with the Company, use
or permit others to use any such Company Property or Confidential Information. Notwithstanding anything to the contrary in this Agreement,
nothing herein shall prevent me from retaining my contact lists, whether in electronic or paper form (e.g. Outlook contacts, rolodex, etc.)
and any documents related to my compensation or benefits.

 

5.             NOTIFICATION
OF NEW EMPLOYER. In the event my relationship with the Company ends, I hereby consent to notification by the Company to my new
employer regarding my rights and obligations under this Agreement and any other agreement by which I am bound.

 

6.             NOTIFICATION
OF RIGHT TO DISCLOSE. I acknowledge receipt of notice that an individual may not be held criminally or civilly liable under any federal
or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official
or to an attorney solely for the purpose of reporting or investigating a suspected violation of law. In addition, I have been given
notice that an individual may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure
of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
Finally, I acknowledge receipt of notice that an individual who files a lawsuit for retaliation by an employer for reporting a suspected
violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding,
if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to
court order.

 

7.            REPRESENTATIONS.
I hereby represent that my relationship with the Company and my performance of all the terms of this Agreement will not result in
a breach of any agreement with a third party, including the breach of any agreement to keep in confidence proprietary information acquired
by me in confidence or in trust prior to my relationship with the Company or to refrain from competing with any third party. I have not
entered into, and I agree I will not enter into, any oral or written agreement in conflict herewith.

 

    3 

     

    

 

8.            NON-SOLICITATION
OF CLIENTS AND CUSTOMERS. I recognize and acknowledge that the Company has a legitimate business interest in protecting the client
and customer goodwill I develop or maintain during my relationship with the Company against solicitation activities and unfair competition
by me for a limited period of time after I leave the Company in order that the Company may maintain, renew or restore its relationships
with such clients or customers. I further recognize and acknowledge that the Company’s relationships with its clients and customers
are among the Company’s most important assets and constitute protectable Confidential Information. Therefore, for a period of two
(2) years following the termination of my direct employment relationship with the Company for any reason whatsoever (whether by virtue
of the Company’s termination, my voluntary termination, or otherwise) (the “Restricted Period”), I shall not, either
individually or on behalf of a person, firm, corporation, partnership, joint venture, association or other entity whatsoever: (i) directly
solicit, or divert business from or endeavor to entice away from the Company, or (ii) directly attempt to solicit or divert business
from, or endeavor to entice away from the Company, any person, firm, corporation, partnership or entity of any kind whatsoever which was
or is a client or customer of the Company and with whom I had personal contact, for which the Company performed services, with respect
to any business, product or service that is competitive with the business, products or services offered by the Company, as of the date
of the termination of the my relationship with the Company.

 

9.             NON-SOLICITATION
OF VENDORS. To prevent the improper use of the Company’s Confidential Information and the resulting unfair competition and misappropriation
of goodwill and other proprietary interests, I agree that during the Restricted Period, I shall not, either individually or
on behalf of a person, firm, corporation, partnership, joint venture, association or other entity whatsoever, directly interfere with,
or otherwise directly cause any provider of services, business partner, independent contractor, vendor, or supplier of the Company to
curtail, sever, or alter its relationship or business with the Company.

 

10.           NON-SOLICITATION
OF EMPLOYEES. During the Restricted Period, I shall not, either individually or on behalf of a person, firm, corporation, partnership,
joint venture, association or other entity whatsoever, directly or indirectly, solicit, induce or attempt to solicit or induce any of
the Company’s managers, directors, officers, employees, consultants or advisors with whom I had personal contact during my relationship
with the Company and before my separation from the Company, to discontinue his, her or its relationship with the Company, provided that
I am not prohibited from recruiting or hiring any person who responds to general advertisements in newspapers and/or electronic and online
media of general circulation that are not targeted specifically towards employees of the Company.

 

11.           REASONABLENESS.
I acknowledge that the duration of the covenants contained in Sections 8, 9 and 10 is fair and reasonable in light of the amount of
compensation, specialized training, education and access to Confidential Information that I am receiving in connection with my relationship
with the Company. It is the Company and my desire and intent that the provisions of this Agreement be enforced to the fullest extent permitted
under applicable law, whether now or hereafter in effect. I agree and understand that the covenants in Sections 8, 9 and 10 are reasonable
and necessary to protect the Company’s Confidential Information and goodwill with its clients, customers and vendors as developed
and maintained by me during my relationship with the Company. I further agree that the provisions in Sections 8, 9 and 10 are reasonable
and narrowly tailored to protect the Company’s legitimate business interests and that I will not suffer any substantial hardship
as a result of enforcement of these provisions. I further acknowledge that I am capable of obtaining suitable employment following the
termination of my relationship with the Company, even though I have agreed not to disclose or use the Company’s Confidential Information
and have agreed to the non-solicitation provisions contained in this Agreement. I further agree that the terms of the non-solicitation
provisions, although they may limit future employment opportunities, do not amount to an industry-wide employment exclusion and, as such,
are neither unduly harsh nor oppressive in curtailing my legitimate efforts to earn a livelihood.

 

    4 

     

    

 

12.           EQUITABLE
REMEDIES. I AGREE THAT ANY BREACH OF THE COVENANTS SET FORTH IN THIS AGREEMENT WILL CAUSE THE COMPANY SUBSTANTIAL AND IRREVOCABLE
DAMAGE AND IRREPARABLE INJURY, AND THAT IT WOULD BE IMPOSSIBLE OR INADEQUATE TO MEASURE AND CALCULATE THE COMPANY’S DAMAGES FROM
ANY SUCH BREACH. ACCORDINGLY, I AGREE THAT IF I BREACH THIS AGREEMENT, THE COMPANY WILL HAVE AVAILABLE, IN ADDITION TO ANY OTHER
RIGHT OR REMEDY AVAILABLE, INCLUDING THE RECOVERY OF DAMAGES FROM ME, THE RIGHT TO SEEK AN INJUNCTION FROM A COURT OF COMPETENT JURISDICTION
RESTRAINING SUCH BREACH OR THREATENED BREACH AND TO SPECIFIC PERFORMANCE OF ANY SUCH PROVISION OF THIS AGREEMENT. I FURTHER AGREE THAT
NO BOND OR OTHER SECURITY SHALL BE REQUIRED IN OBTAINING SUCH EQUITABLE RELIEF AND I HEREBY CONSENT TO THE ISSUANCE OF SUCH INJUNCTION
AND TO THE ORDERING OF SPECIFIC PERFORMANCE.

 

13.           GOVERNING
LAW, ARBITRATION. THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE. THE PARTIES
AGREE TO USE THEIR BEST EFFORTS TO AMICABLY RESOLVE ANY DISPUTE ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE RELATIONSHIP. ANY
CONTROVERSY, CLAIM OR DISPUTE THAT CANNOT BE SO RESOLVED SHALL BE SETTLED BY FINAL BINDING ARBITRATION IN ACCORDANCE WITH THE EMPLOYMENT
RULES OF THE AMERICAN ARBITRATION ASSOCIATION AND JUDGMENT UPON THE AWARD RENDERED BY THE ARBITRATOR MAY BE ENTERED IN ANY COURT
HAVING JURISDICTION THEREOF. ANY SUCH ARBITRATION SHALL BE CONDUCTED IN NEW YORK CITY, NEW YORK OR SUCH OTHER PLACE AS MAY BE MUTUALLY
AGREED UPON BY THE PARTIES. WITHIN FIFTEEN (15) DAYS AFTER THE COMMENCEMENT OF THE ARBITRATION, THE PARTIES SHALL MUTUALLY AGREE UPON
A SINGLE ARBITRATOR, AND IF THEY CANNOT SO AGREE WITHIN SUCH TIME PERIOD, THE SINGLE ARBITRATOR SHALL BE APPOINTED BY THE AMERICAN ARBITRATION
ASSOCIATION. THE ARBITRATOR SHALL HAVE EXCLUSIVE AUTHORITY TO DETERMINE THE FORMATION, EXISTENCE, VALIDITY, ENFORCEABILITY, INTERPRETATION
OR SCOPE OF THE PARTIES’ AGREEMENT TO ARBITRATE. UPON APPLICATION OF ANY PARTY, THE ARBITRATOR MAY REQUIRE SPECIFIC PERFORMANCE
OF ANY PROVISION OF ANY AGREEMENT BETWEEN THE PARTIES, INCLUDING THE AWARD OF EMERGENCY, TEMPORARY OR PRELIMINARY INJUNCTIVE RELIEF.
A PARTY ALSO MAY, WITHOUT WAIVING ANY OTHER REMEDY, SEEK FROM ANY COURT HAVING JURISDICTION ANY INTERIM OR PROVISIONAL RELIEF THAT IS
NECESSARY TO PROTECT THE RIGHTS OR PROPERTY OF THAT PARTY PENDING THE ARBITRATOR’S APPOINTMENT OR DECISION ON THE MERITS OF THE
DISPUTE. IN ADDITION, A PARTY MAY, WITHOUT WAIVING ANY OTHER REMEDY, SEEK RELIEF FROM ANY COURT HAVING JURISDICTION FOR ANY CLAIM THAT
IS NON-ARBITRABLE UNDER APPLICABLE STATE OR FEDERAL LAW. EACH PARTY SHALL BEAR ITS OWN COSTS AND EXPENSES IN AN EQUAL SHARE OF THE ARBITRATOR’S
EXPENSES AND ADMINISTRATIVE FEES OF ARBITRATION. THE PARTIES AGREE (I) NO ARBITRATION PROCEEDING HEREUNDER SHALL BE CERTIFIED AS
A CLASS ACTION OR PROCEED AS A CLASS ACTION, COLLECTIVE ACTION OR ON A BASIS INVOLVING CLAIMS BROUGHT IN A PURPORTED REPRESENTATIVE
CAPACITY ON BEHALF OF OTHER PERSONS SIMILARLY SITUATED, AND (II) NO ARBITRATION PROCEEDING HEREUNDER SHALL BE CONSOLIDATED WITH,
OR JOINED IN ANY WAY WITH, ANY OTHER ARBITRATION PROCEEDING.

 

    5 

     

    

 

14.           ASSISTANCE
IN LITIGATION. During and following my relationship with the Company, I agree, upon reasonable notice and for a reasonable time
following the termination of my relationship with the Company, to furnish such information and proper assistance to the Company as may
be reasonably required by the Company with any litigation or audit in which it is, or may become, a party. The Company’s requests
pursuant to this Section shall take into consideration my personal and business commitments and the amount of notice provided to
me. The Company will also reimburse me, if legally permissible, for reasonable out of pocket and other incidental expenses that I incur
as a result of my cooperation pursuant to this paragraph (including reasonable attorneys’ fees, if reasonably necessary).

 

15.           ENTIRE
AGREEMENT. This Agreement sets forth the entire agreement and understanding between the Company and the undersigned relating to the
subject matter hereof and merges all prior discussions between the parties with respect to such subject matter.

 

16.           AMENDMENTS.
The parties hereby agree that, notwithstanding the provisions of the Electronic Signatures in Global and National Commerce Act, no
modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing
signed by the party to be charged. Any subsequent change or changes in duties, salary, or compensation will not affect the validity or
scope of this Agreement.

 

17.           SEVERABILITY.
If one or more of the provisions in this Agreement are deemed void or voidable under applicable law, then the remaining provisions
will continue in full force and effect without the inclusion of any such provisions.

 

18.           SUCCESSORS
AND ASSIGNS. I agree that I will not assign this Agreement or any rights and obligations hereunder to any third party. This Agreement
will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company and
its successors and assigns.

 

19.            HEADINGS.
The section headings herein contained have been inserted for convenience of reference only and shall not be used to interpret, construe
or in any way affect the meaning or interpretation of the terms and provisions hereof. Without limiting the generality of the foregoing,
the restrictions and obligations set forth herein shall remain in full force and effect whether the undersigned’s efforts on behalf
of the Company are performed as an employee, consultant or as a member providing services for the benefit of the Company.

 

21.           WAIVER.
A waiver by any party hereto of any condition or the breach of any term, covenant, representation or warranty contained in this Agreement,
whether by conduct or otherwise, in any one or more instances, shall not be deemed or construed as a further or continuing waiver of any
such condition or the breach of any other term, covenant, representation or warranty set forth in this Agreement.

 

22.           SURVIVAL.
Sections 2, 4, 6, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18 and 21 shall survive any termination or expiration of this Agreement.

 

23.           COUNTERPARTS.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

 

In Witness Whereof, this Proprietary
Matters Agreement has been executed with the intent it be effective as of [Effective Date].

 

    6 

     

    

 

	 	MIDWEST HOLDING INC.
	 	 
	 	 
	 	By: :	/s/ Mike Minnich
	 	 	Mike Minnich
	 	 	Co-CEO
	 	 	 
	 	 	 
	 	GEORGETTE C. NICHOLAS
	 	 
	 	 
	 	/s/Georgette C. Nicholas
	 	Name: Georgette C. Nicholas
	 	 
	 	Date: September 8, 2021
	 	 	 

THIS AGREEMENT CONTAINS AN ARBITRATION PROVISION

WHICH MAY BE ENFORCED

 

    7 

     

    

 

EXHIBIT 1

 

1.List of Prior Inventions and Original Works
of Authorship

 

	Title	Date	Identifying Number or Brief Description

 

If no Prior Inventions are listed above, I
represent that there are no such Prior Inventions.

 

2.             List
of Prior Non-competition and Non-solicitation Restrictions

 

	Title	Date	Identifying Number or Brief Description

 

If no prior non-competition and non-solicitation
restrictions are listed above, I represent that there are no such restrictions.

 

	 	GEORGETTE C. NICHOLAS
	 	 
	 	 
	 	/s/ Georgette C. Nicholas
	 	Name
	 	 
	 	Date: September 8, 2021

 

    8 

     

    

 

Exhibit C

 

SEVERANCE AGREEMENT AND RELEASE

 

This Severance Agreement and
Release (this “Agreement”) is entered into by and between Georgette C. Nicholas (“Employee”) and Midwest Holding
Inc. (the “Company”). Employee and the Company are sometimes collectively referred to as the “Parties.” All
terms not otherwise defined herein shall have the same meaning as set forth in the Employment Agreement between the Parties dated ________________,
2021.

 

1.             Employee’s
employment with the Company is terminated effective _____________, 20___ (the “Termination Date”). The Parties have agreed
to avoid and resolve any alleged existing or potential disagreements between them arising out of or connected with Employee’s employment
with the Company and the termination of such employment. The Company expressly disclaims any wrongdoing or any liability to Employee.

 

2.             The
Company acknowledges that it will pay Employee for Base Salary earned through the Termination Date and reimburse Employee for properly
documented and timely submitted business expenses, if any, pursuant to the Company’s expense reimbursement policies. All benefits
that Employee currently receives from the Company shall terminate on the Termination Date; provided, however, that Employee’s health
and dental benefits (if applicable) may continue, consistent with Company policy, through the last day of the month that includes the
Termination Date. Moreover, the termination of any health insurance benefits is subject to Employee’s rights under the Consolidated
Omnibus Budget Reconciliation Act (“COBRA”).

 

3.             In
exchange for Employee’s execution of this Agreement, and Employee’s performance of his/her obligations hereunder, the Company
agrees to provide Employee the following severance benefits after the expiration of the revocation period described in Paragraph 20,
below, at which time this Agreement becomes effective (“Effective Date”), provided Employee has not revoked this Agreement
as described in Paragraph 20:

 

[Insert Applicable Severance Benefits]

 

Employee specifically acknowledges
and agrees that this consideration exceeds the amount Employee would otherwise be entitled to receive upon termination of Employee’s
employment and that such severance benefit are in exchange for entering into and performing this Agreement. Employee agrees that Employee
will not at any time seek consideration from the Company other than what is set forth in this Agreement. Employee specifically acknowledges
and agrees that the Company has made no representations to Employee regarding the tax consequences of any amounts received by Employee
or for Employee’s benefit pursuant to this Agreement, and Employee has not relied on any representation or lack of representation
by the Company. Employee remains wholly responsible for the tax consequences regarding the amounts to be received.

 

4.             Except
to the extent prohibited by law, Employee and Employee’s heirs, executors, administrators, successors and assigns hereby fully RELEASE
the Company and each of its direct and indirect subsidiaries, affiliates and parents and each of their respective predecessors, successors
and past and present direct and indirect stakeholders, directors, officers, employees, contractors, representatives, agents and assigns
(the “Company Releasees”) from any and all claims, complaints, causes of action or demands, of whatever kind or nature, that
Employee now has or has ever had against the Company or any of the Company Releasees, arising from or relating to Employee’s employment
with or discharge from the Company, whether known or unknown to Employee at the time of Employee’s execution of this Agreement,
including, but not limited to: wrongful or tortious termination, specifically including, but not limited to, actual or constructive termination
in violation of public policy; military leave, reinstatement, or related rights; claims under common law, statute or contract, specifically
including, but not limited to, implied or express employment contracts and/or estoppel; discrimination, retaliation and/or any other claims
under any federal, state or local statute or regulation, specifically including but not limited to any claims Employee may have under
the WARN Act, the Fair Labor Standards Act, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Americans
with Disabilities Act, Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, 42 U.S.C. Section 1981,
the Family and Medical Leave Act, and the Employee Retirement Income Security Act, all as amended; any and all claims brought under any
applicable state or local employment, discrimination or other statutes; any claims brought under any federal, state or local statute or
regulation with respect to nonpayment of wages, severance pay, or other compensation (including, but not limited to, bonuses); and libel,
slander, fraud, misrepresentation, or breach of contract other than a breach of this Agreement. THIS AGREEMENT CONTAINS A GENERAL RELEASE
OF ALL CLAIMS. This release specifically excludes claims, charges, complaints, causes of action or demands of whatever kind or nature:
(a) that arise after the Termination Date, including the right to enforce this Agreement; (b) that cannot be released as a matter
of law, including Employee’s rights to COBRA, workers’ compensation, and unemployment insurance; (c) to accrued, vested
benefits under any employee benefit, stock, savings, insurance or pension plan of the Company; or (d) to indemnification, contribution,
advancement or defense as provided by and in accordance with the terms of the Company by-laws, articles of incorporation, liability insurance
coverage, or applicable law.

 

    2 

     

    

 

5.             Nothing
in this Agreement shall preclude or interfere with Employee’s rights under federal, state or local civil rights or employment discrimination
laws to file a complaint with any federal, state or local agency or self-regulatory organization charged with enforcing such laws, including,
but not limited, to the Equal Employment Opportunity Commission (“EEOC”). Nor shall this Agreement be construed to prevent
Employee from assisting in, cooperating with or participating in any investigations or proceedings by such agency or self-regulatory organization
pursuant to a lawful subpoena or equivalent order. None of the foregoing acts by Employee shall constitute a breach of any non-disparagement,
confidentiality or cooperation clauses or any other clause of this Agreement. Notwithstanding the foregoing, Employee acknowledges and
agrees that Employee hereby waives any and all rights Employee may have to recovery of any damages (whether monetary or otherwise) in
connection with any complaint or charge Employee may file pursuant to this Paragraph and that the amount specified in Paragraph 3 herein
is sufficient consideration for any such claims.

 

6.             Employee
represents and warrants that Employee has no pending disputes, differences, grievances, charges, complaints, litigation, lawsuits, or
actions against any of the Company Releasees or with any local, state or federal agency or court arising from or related to Employee’s
employment relationship with or separation from the Company. Employee hereby warrants and represents that Employee has not assigned, alienated,
hypothecated or in any other way transferred (in whole or in part) to any other person, organization or entity any claims, demands, losses,
actions or rights of action against the Company, known or unknown, of whatever character and nature, arising from or related in any way
to Employee’s employment with or separation from the Company, or any claim Employee may have against any of the Company Releasees.

 

7.             Employee
affirmatively states and represents that upon Employee’s receipt of pay for Employee’s hours worked through Termination Date,
as provided in Paragraph 2 above, Employee will have received all compensation to which Employee became entitled during Employee’s
employment with the Company and that no other wages or compensation remain payable to Employee.

 

8.             Employee
will not make any disparaging remarks regarding the Company, its business, products and services, or any of its directors, officers, employees,
contractors, representatives, agents and assigns, to any third party, whether in private or in public. The Company, will direct its’
directors and senior management not to make any disparaging remarks regarding Employee, whether in private or in public. Nothing in this
Paragraph is intended to restrict Employee from engaging in activity protected by the National Labor Relations Act or prohibit Employee,
the Company or any of its’ directors or senior managers from testifying truthfully under oath.

 

    3 

     

    

 

9.             Employee
will not disclose any Confidential Information (as herein defined) and (a) shall not permit any third party access to the Confidential
Information; (b) shall use the same degree of care to protect the Confidential Information as the Company uses to protect its Confidential
Information; and (c) shall take any other actions that are reasonable, necessary or appropriate to ensure the continued confidentiality
and protection of the Confidential Information. “Confidential Information” means proprietary information of the Company, including,
but not limited to, customer information, customer or vendor lists or information obtained through customer, customer or vendor contacts,
trade secrets, business plans, marketing plans, financial information or reports and any other information relating to the business of
the Company or any affiliate that would be detriment of the Company if disclosed or to any other third party; provided, however, that
 “Confidential Information” shall not include information that is (i) part of the public domain (other than as a result
of a breach of this Agreement); (ii) generally known within the industry; or (iii) known to Employee prior to her employment
with the Company. Employee shall treat all Confidential Information and all other nonpublic information obtained during Employee’s
employment by the Company as confidential and shall not, without written authorization from the Company, release or share such information
with any third party, except as may be required by law or pursuant to an order by any court or tribunal of competent jurisdiction.

 

10.           Employee
affirmatively states and represents that the Company has not taken any retaliatory personnel action against Employee because Employee
disclosed, or threatened to disclose, to any appropriate governmental agency, an activity, policy, or practice of the Company that Employee
believes to be in violation of a law, rule, or regulation; for providing information to, or testifying before, any appropriate governmental
agency, person, or entity conducting an investigation, hearing, or inquiry into an alleged violation of a law, rule, or regulation by
the Company; or for objecting to, or refusing to participate in, any activity, policy, or practice by the Company which Employee believes
to be in violation of a law, rule, or regulation.

 

11.           Employee
warrants that Employee has, or, prior to becoming entitled to any payment hereunder, Employee shall, deliver to the Company all memoranda,
notes, plans, records, reports, computer files, printouts and software and other documents and data (and copies thereof) relating to the
Confidential Information, or the business of the Company that Employee may then possess or have under his/her control; provided, however,
nothing herein shall prevent Employee from retaining documents related to her compensation and benefits. If Employee fails or refuses
to comply with the provisions of this Paragraph, the Company may, at its option, cancel and revoke this Agreement.

 

12.           The
Company requests that prior to reporting any actual or perceived violation of law to any governmental entity, Employee first notify the
Company of any potential legal or compliance issue to allow the Company the opportunity to investigate and appropriately report any compliance
matter brought to its attention by Employee. Nothing in this Paragraph is intended to impede Employee’s right to report possible
violations of law that are protected under the whistleblower provisions of local, state or federal law, including reports to any governmental
agency or entity, and Employee is not required to seek the Company’s permission prior to making such reports.

 

13.           Employee
acknowledges receipt of notice that an individual may not be held criminally or civilly liable under any federal or state trade secret
law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney
solely for the purpose of reporting or investigating a suspected violation of law. In addition, Employee has been given notice that an
individual may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret
that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Finally, Employee
acknowledges receipt of notice that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation
of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if
the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court
order.

 

14.           In
response to inquiries regarding Employee’s employment with the Company, the Company, by and through its speaking agent(s), agrees
to provide a neutral reference and to report the following information: Employee’s date of hire, the date Employee’s employment
ended, and Employee’s rates of pay.

 

    4 

     

    

 

15.           Employee
warrants that no promise or inducement has been offered for this Agreement other than as set forth herein and that this Agreement is executed
without reliance upon any other promises or representations, oral or written.

 

16.           This
Agreement constitutes the entire understanding between the Parties on the subject matter contained herein and supersedes all negotiations,
representations, prior discussions and preliminary agreements between the Parties with respect to the subject matter herein. This Agreement
does not supersede any agreements, including, but not limited to, the Proprietary Matters Agreement or any restrictive covenants that
were in effect immediately prior to the date of this Agreement and which, by their terms, survive the termination of Employee’s
employment. Employee acknowledges that provisions contained within any agreements that Employee signed with the Company and which expressly
survive Employee’s employment, shall remain in full force and effect and survive his/her employment with the Company as provided
by the terms of any such agreements. Such terms are expressly incorporated herein.

 

17.           If
any provision of this Agreement or compliance by Employee or the Company with any provision of this Agreement constitutes a violation
of any law, or is or becomes unenforceable or void, then such provision, to the extent only that it is in violation of law, unenforceable
or void, shall be modified to the extent necessary so that it is no longer in violation of law, unenforceable or void, and such provision
will be enforced to the fullest extent permitted by law. If such modification is not possible, such provision, to the extent it is in
violation of law, unenforceable or void, will be deemed severable from the remaining provisions of this Agreement, which remaining provisions
will remain binding on both Employee and the Company.

 

18.           This
Agreement will be governed by the laws of the State of Delaware (without regard to its choice-of-law provisions), which Employee agrees
bears a substantial relationship to the Parties and to this Agreement. The state and federal courts located in Wilmington, Delaware shall
have exclusive jurisdiction of any lawsuit arising from or relating to Employee’s employment with, or termination from, the Company,
or arising from or relating to this Agreement, and Employee expressly consents to personal jurisdiction in Delaware courts and waives
any right to contest the same. The prevailing party in any such lawsuit will be entitled to an award of attorneys’ fees and reasonable
litigation costs. The foregoing excludes any claim challenging the validity of Employee’s waiver of rights under the Age Discrimination
in Employment Act or charge asserting age discrimination.

 

19.           Employee
agrees that Employee will indemnify and hold the Company harmless from and against any and all losses, liabilities, costs, damages or
expenses incurred by the Company or any Company Releasee (including, without limitation, reasonable attorneys’ fees) arising out
of or resulting from any breach of this Agreement by Employee. Employee further agrees that if Employee challenges this Agreement, files
any claims against the Company arising from or relating to Employee’s employment with, or termination from, the Company, excluding
any claim challenging the validity of Employee’s waiver of rights under the Age Discrimination in Employment Act, or otherwise fails
to abide by the terms of this Agreement, as determined by a court of competent jurisdiction, (a) Employee will return all moneys
and benefits received by Employee from the Company pursuant to this Agreement and (b) the Company may elect, at its option and without
waiver of any other rights or remedies it may have, not to pay or provide any unpaid moneys or benefits.

 

20.           Employee
specifically agrees and acknowledges that (A) Employee’s waiver of rights under this Agreement is knowing and voluntary as
required under the Older Workers’ Benefit Protection Act and Age Discrimination in Employment Act; (B) Employee understands
the terms of this Agreement; (C) Employee has been advised in writing by the Company to consult with an attorney prior to executing
this Agreement; (D) the Company has given Employee a period of up to twenty-one (21) days within which to consider this Agreement
and that if Employee executes this Agreement within such period, Employee waives the remainder of the period and that modifications to
this Agreement during such period, whether material or immaterial, do not restart the running of such period; (E) following Employee’s
execution of this Agreement, Employee has seven (7) days in which to revoke Employee’s agreement to this Agreement and that
if Employee chooses not to so revoke, this Agreement shall then become effective and enforceable and the payment and extension of benefits
listed below shall then be made to Employee in accordance with the terms of this Agreement; and (F) nothing in this Agreement shall
be construed to prohibit Employee from filing a charge or complaint, including a challenge to the validity of the waiver provision of
this Agreement, with the Equal Employment Opportunity Commission or participating in any investigation conducted by the Equal Employment
Opportunity Commission; provided, however, that Employee has waived any right to monetary relief. To cancel this Agreement, Employee understands
that Employee must deliver a written revocation to 2900 South 70th Street, Suite 400, Lincoln, Nebraska 68510, Attention:
General Counsel, by 5:00 p.m. on the seventh day after Employee executes this Agreement. If Employee revokes this Agreement, it will
not become effective or enforceable and Employee will not be entitled to any of the benefits set forth in this Agreement.

 

    5 

     

    

 

21.           EMPLOYEE
ACKNOWLEDGES AND AGREES THAT EMPLOYEE HAS CAREFULLY READ AND VOLUNTARILY SIGNED THIS AGREEMENT, THAT EMPLOYEE HAS HAD AN OPPORTUNITY TO
CONSULT WITH AN ATTORNEY OF EMPLOYEE’S CHOICE, AND THAT EMPLOYEE SIGNS THIS AGREEMENT WITH THE INTENT OF RELEASING THE COMPANY AND
ITS OFFICERS, DIRECTORS, EMPLOYEES, CONTRACTORS, REPRESENTATIVES, AGENTS AND ASSIGNS FROM ANY AND ALL CLAIMS.

 

22.           This
Severance Agreement and Release shall inure to the benefit of and be binding upon the Parties, as well as their successors, heirs and
assigns.

 

23.           This
Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, including any signed electronic
facsimile copies of this Agreement, and all such counterparts together shall be deemed to constitute one and the same instrument.

 

24.           Changes
in this Agreement, whether by additions, waivers, deletions, amendments or modifications, may be accomplished only by a writing signed
by both Employee and the Company.

 

[Remainder of Page Intentionally Left Blank
 – Signature Page Follows]

 

    6 

     

    

 

	ACCEPTED AND AGREED TO:	 	 
	 	 	 
	Midwest Holding Inc.	 	Georgette C. Nicholas
	 	 	 
	 	 	 
	By:	 	 	By:	 
	 	[Name]	 	 	Georgette
C. Nicholas
	 	[Title]	 	 
	Date:	 	 	Date:	 

 

    7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]